SCHEMBL24307477

SCHEMBL24307477

COC(=O)C1CN(c2ccc(N3CCCC3=O)cn2)C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.53
GPR119 Q8TDV5 1/20 0.51
AKR1C3 P42330 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 3/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 1/20 0.41
HRH1 P35367 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 4/20 0.41
HTT P42858 1/20 0.41
TSHR P16473 3/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
CNR2 P34972 1/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21299130 0.86 HRH3 (0.51) HRH3GPR119AKR1C3ALDH1A1HPGD
SCHEMBL24307894 0.86 HRH3 (0.53) HRH3AKR1C3ALDH1A1HPGDSMN1; SMN2
SCHEMBL21299126 0.85 HRH3 (0.52) HRH3AKR1C3ALDH1A1HPGDSMN1; SMN2
SCHEMBL21299070 0.84 HRH3 (0.51) HRH3GPR119AKR1C3ALDH1A1HPGD
SCHEMBL24307884 0.81 HRH3 (0.48) HRH3GPR119AKR1C3ALDH1A1HPGD
SCHEMBL24307755 0.81 HRH3 (0.48) HRH3AKR1C3ALDH1A1HPGDSMN1; SMN2
SCHEMBL24308105 0.80 AKR1C3 (0.43) HRH3AKR1C3ALDH1A1HPGDSMN1; SMN2
SCHEMBL21299020 0.77 HRH3 (0.55) HRH3AKR1C3ALDH1A1HPGDMAPT
SCHEMBL5483871 0.76 ALDH1A1 (0.64) ALDH1A1HPGDSMN1; SMN2MAPTGAA
SCHEMBL23168357 0.74 HRH3 (0.60) HRH3GPR119AKR1C3HRH1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3585775-B1 AZETIDINE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS SANOFI SA (FR) 2022-04-06 EP disclosed